Tag: immune response

The immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is complex and variable by disease severity, and the immunopathology of severe COVID-19 has been well studied since the inception of the pandemic. A broad spectrum of abnormal and dysregulated immune responses have been observed amongst the moderately to critically ill. However, it is

An estimated 10% to 30% of people who get Covid-19 suffer from lingering symptoms of the disease, or what’s known as “long Covid.” Judy Dodd, who lives in New York City, is one of them. She spent nearly a year plagued by headaches, shortness of breath, extreme fatigue and problems with her sense of smell,

Scientists have reported that in most cases, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, mildly infects infants. However, around 10% of infants experienced severe COVID-19 infection who required advanced medical treatments. In rare cases, even asymptomatic infection can result in Multisystem Inflammatory Syndrome in

Scientists have reported that in most cases, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, mildly infects infants. However, around 10% of infants experienced severe COVID-19 infection who required advanced medical treatments. In rare cases, even asymptomatic infection can result in Multisystem Inflammatory Syndrome in

Finding effective and safe vaccines is crucial in the fight against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease 2019 (COVID-19). As a vital component of a subunit vaccine, the adjuvant strengthens the antigen-induced immune responses. Researchers at the National Center for Nanoscience and Technology of China, the

Six months after it was controversially hailed by Trump administration officials as a "breakthrough" therapy to fight the worst effects of Covid-19, convalescent plasma appears to be on the ropes. The treatment that infuses blood plasma from recovered Covid patients into people newly infected in hopes of boosting their immune response has not lived up

In a study published online February 25, 2021 in The New England Journal of Medicine, a repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Results of the Phase III clinical trial, conducted by an international team led by senior author Atul Malhotra, MD, research chief

The coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to wreak havoc across the globe. Scientists are racing to develop effective therapeutic regimens to combat the infection. One of therapy currently used to stimulate a robust immune response against the virus is monoclonal antibodies, a treatment used for

The coronavirus disease 2019 (COVID-19) is a transmissible viral disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for the ongoing global pandemic. The virus was first detected in Wuhan, China, at the end of 2019 and to date has caused over 109 million infections worldwide. With over 2.4 million

Neutralizing antibodies develop within two weeks of a SARS-CoV-2 infection, but their durability and intensity can vary by individual, prompting concerns about the prospects of long-lasting immunity and efficacy of COVID-19 vaccines. In a PLOS ONE paper, published online February 11, 2021, researchers at University of California San Diego School of Medicine report that individual

Research has repeatedly shown that women have a stronger immune response to infections than men. Studies from as early as the 1940s have elucidated that women possess an enhanced capability of producing antibodies. Image Credit: Peterschreiber.media/Shutterstock.com Even though this builds an effective resistance barrier to infections, women have a higher predisposition to autoimmunity caused by

Genital warts and the flu don't seem to have much in common, other than that they are both caused by viruses. But now, researchers are testing whether a cream that's commonly used to treat genital warts could also help boost the protection of flu vaccines in the event of a pandemic. In a study that began earlier this